Literature DB >> 30231392

Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine.

John D Hainsworth1, F Anthony Greco1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30231392     DOI： 10.1200/EDBK_100014

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


× No keyword cloud information.
  10 in total

1.  Integration of a patient-centred MUO/CUP service within a new acute oncology service: challenges and rewards.

Authors:  Sonali Dasgupta; Wendy B Hyland; Conn Haughey; Sohail Mughal; Adam Henry; Celia Diver-Hall
Journal:  Future Healthc J       Date:  2021-03

2.  Metastases with definitive pathological diagnosis but no detectable primary tumor: A surveillance epidemiology and end results-based study.

Authors:  Lianyuan Tao; Haibo Yu; Yadong Dong; Guanjing Tian; Zhiyuan Ren; Deyu Li
Journal:  Cancer Med       Date:  2019-08-13       Impact factor: 4.452

Review 3.  Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.

Authors:  Antonella Argentiero; Antonio Giovanni Solimando; Oronzo Brunetti; Angela Calabrese; Francesco Pantano; Michele Iuliani; Daniele Santini; Nicola Silvestris; Angelo Vacca
Journal:  Cancers (Basel)       Date:  2019-08-29       Impact factor: 6.639

4.  The Annual Meeting of the Thai Gynecologic Cancer Society 2019: Meeting report.

Authors:  Kittipat Charoenkwan; Jatupol Srisomboon
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

5.  Clinical and immune profiling for cancer of unknown primary site.

Authors:  Koji Haratani; Hidetoshi Hayashi; Takayuki Takahama; Yasushi Nakamura; Shuta Tomida; Takeshi Yoshida; Yasutaka Chiba; Takahiro Sawada; Kazuko Sakai; Yoshihiko Fujita; Yosuke Togashi; Junko Tanizaki; Hisato Kawakami; Akihiko Ito; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  J Immunother Cancer       Date:  2019-09-13       Impact factor: 13.751

6.  The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" by J Abraham et al.

Authors:  F Anthony Greco
Journal:  Transl Oncol       Date:  2021-08       Impact factor: 4.243

Review 7.  Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?

Authors:  Elie Rassy; Tarek Assi; Nicholas Pavlidis
Journal:  Br J Cancer       Date:  2020-02-11       Impact factor: 7.640

8.  Phase 2 study of pembrolizumab in patients with advanced rare cancers.

Authors:  Aung Naing; Funda Meric-Bernstam; Bettzy Stephen; Daniel D Karp; Joud Hajjar; Jordi Rodon Ahnert; Sarina A Piha-Paul; Rivka R Colen; Camilo Jimenez; Kanwal P Raghav; Renata Ferrarotto; Shi-Ming Tu; Matthew Campbell; Linghua Wang; Sarjeel H Sabir; Coya Tapia; Chantale Bernatchez; Michael Frumovitz; Nizar Tannir; Vinod Ravi; Saria Khan; Jeane M Painter; Abulrahman Abonofal; Jing Gong; Anas Alshawa; Lacey M McQuinn; Mingxuan Xu; Sara Ahmed; Vivek Subbiah; David S Hong; Shubham Pant; Timothy A Yap; Apostolia M Tsimberidou; Ecaterina E Ileana Dumbrava; Filip Janku; Siqing Fu; Richard M Simon; Kenneth R Hess; Gauri R Varadhachary; Mouhammed Amir Habra
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

9.  A Novel XGBoost Method to Infer the Primary Lesion of 20 Solid Tumor Types From Gene Expression Data.

Authors:  Sijie Chen; Wenjing Zhou; Jinghui Tu; Jian Li; Bo Wang; Xiaofei Mo; Geng Tian; Kebo Lv; Zhijian Huang
Journal:  Front Genet       Date:  2021-02-03       Impact factor: 4.599

10.  Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).

Authors:  Hamidreza Aboulkheyr Es; Hamid Mahdizadeh; Amir Abbas Hedayati Asl; Mehdi Totonchi
Journal:  Sci Rep       Date:  2021-07-23       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.